怎样实现乙型肝炎临床治愈

doi:10.3969/j.issn.1672-5069.2019.03.001

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (3): 305-308.doi: 10.3969/j.issn.1672-5069.2019.03.001

• 述评 • 下一篇

怎样实现乙型肝炎临床治愈

高志良, 朱翔

510630 广州市中山大学附属第三医院感染性疾病科

收稿日期:2019-03-07 出版日期:2019-05-10 发布日期:2019-05-15
作者简介:高志良,肝病医院副院长,感染性疾病科主任; 以通讯作者发表论文近300 篇,其中SCI 收录30 余篇,在本专业国际顶级杂志,如Hepatology 和Journal of Hepatology 发表系列论文5篇; 主持国家科技重大专项子课题4 项,国家自然科学基金项目2项和省市各级科研项目累计科研基金超过2500万; 荣获国家教育部、广东省科技进步奖一等奖等5项; 现任中国肝炎防治基金会发起的“中国慢性乙型肝炎临床治愈（珠峰）工程”项目执委会主任; Tel：020-85252372,E-mail：gaozhl@mail.sysu.edu.cn

How to achieve the clinical cure of hepatitis B

Gao Zhiliang, Zhu Xiang

Department of Infectious Diseases, Third Affiliated Hospital,Sun Yat-sen University,Guangzhou 510630

Received:2019-03-07 Online:2019-05-10 Published:2019-05-15

摘要/Abstract

关键词: 慢性乙型肝炎, 临床治愈, 治疗策略

Key words: Hepatitis B, Clinical cure, Treatment strategy

高志良, 朱翔. 怎样实现乙型肝炎临床治愈[J]. 实用肝脏病杂志, 2019, 22(3): 305-308.

Gao Zhiliang, Zhu Xiang. How to achieve the clinical cure of hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 305-308.

[1] Block TM,Gish R,Guo H,et al. Chronic hepatitis B:what should be the goal for new therapies Antiviral Res,2013,98(1):27-34.
[2] McMahon BJ,Holck P,Bulkow L,et al. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med,2001,135(9):759-768.
[3] Liaw YF,Sheen IS,Chen TJ,et al.Incidence,determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology,1991,13(4):627-631.
[4] Chu CM,Liaw YF.HBsAg seroclearance in asymptomatic carriers of high endemic areas:appreciably high rates during a long-term follow-up. Hepatology,2007,45(5):1187-1192.
[5] McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology,2009,49(Suppl 5):S45-55.
[6] Buti M,Tsai N,Petersen J,et al.Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci,2015,60(5):1457-1464.
[7] European Association For The Study Of The L. EASL clinical practice guidelines:Management of chronic hepatitis B virus infection. J Hepatol,2012,57(1):167-185.
[8] Chevaliez S,Hezode C,Bahrami S,et al.Long-term hepatitis B surface antigen(HBsAg) kinetics during nucleoside/nucleotide analogue therapy:finite treatment duration unlikely. J Hepatol,2013,58(4):676-683.
[9] Lau GK,Piratvisuth T,Luo KX,et al.Peginterferon alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B. New Engl J Med,2005,352(26):2682-2695.
[10] Marcellin P,Lau GK,Bonino F,et al.Peginterferon alfa-2a alone,lamivudine alone,and the two in combination in patients with HBeAg-negative chronic hepatitis B. New Engl J Med,2004,351(12):1206-1217.
[11] Marcellin P,Boyer N,Asselah T.Medical therapy of patients affected by HBeAg-negative chronic hepatitis B. Minerva Gastroenterol Dietol,2006,52(1):23-38.
[12] Marcellin P,Bonino F,Lau GK,et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology,2009,136(7):2169-2179,e1-4.
[13] Cao Z,Liu Y,Ma L,et al.A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology,2017,66(4):1058-1066.
[14] Buster EH,Hansen BE,Lau GK,et al.Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology,2009,137(6):2002-2009.
[15] Janssen HL,van Zonneveld M,Senturk H,et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet,2005,365(9454):123-129.
[16] Lin B,Ha NB,Liu A,et al.Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol,2013,28(5):855-860.
[17] Zoutendijk R,Hansen BE,van Vuuren AJ, et al. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis,2011,204(3):415-418.
[18] Marcellin P,Ahn SH,Chuang WL,et al.Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Therapeut,2016,44(9):957-966.
[19] Marcellin P,Ahn SH,Ma X,Caruntu FA,et al.Combination of tenofovir disoproxil fumarate and peginterferon alpha-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology,2016,150(1):134-144,e10.
[20] Hu P,Shang J,Zhang W,et al.HBsAg loss with peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos(t)ide analog:New Switch Study. J Clin Transl Hepatol,2018,6(1):25-34.
[21] Ning Q,Han M,Sun Y,et al.Switching from entecavir to pegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:a randomised open-label trial (OSST trial). J Hepatol,2014,61(4):777-784.
[22] Gao Z,Zhu X,Lin B,et al.The optimizing treatment of peg interferon alfa in Hbeag negative chronic hepatitis B patients with low level HBsAg:A multicenter real world study (Interferon Cure Study,I CURE Study). Hepatology,2018,68(S1):246A.
[23] Blank A,Markert C,Hohmann N,et al.First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. J Hepatol,2016,65(3):483-489.
[24] Cai D,Mills C,Yu W,et al.Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother,2012,56(8):4277-4288.
[25] Ahmed M,Wang F,Levin A,et al.Targeting the achilles heel of the hepatitis B virus:a review of current treatments against covalently closed circular DNA. Drug Discov Today,2015,20(5):548-561.
[26] Schluep T,Lickliter J,Hamilton J,et al.Safety,tolerability,and pharmacokinetics of ARC-520 injection,an RNA interference-based therapeutic for the treatment of chronic hepatitis B virus infection,in healthy volunteers. Clin Pharmacol Drug Dev,2017,6(4):350-362.

怎样实现乙型肝炎临床治愈

How to achieve the clinical cure of hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[6]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[7]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[8]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[9]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[10]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[11]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[12]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.
[13]	闫瑞斌, 马淑梅, 卓玛, 乔志忠, 刘潇. 慢性乙型肝炎患者血清MMP-2和TIMP-2水平及超声检查指标评估肝纤维化分期意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 506-509.
[14]	张亚飞, 叶珺, 谢琴秀, 邹桂舟, 李家斌, 李旭, 张振华. 不同医院无创性肝纤维化指标预测慢性乙型肝炎患者肝纤维化效能差异分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 510-513.
[15]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.